

Q3

arjo
EMPOWERING MOVEMENT

INTERIM REPORT

JANUARY-SEPTEMBER 2026

Solid growth and a strategy for greater value creation

July–September 2026 in brief

- Net sales increased to SEK 2,849 M (2,646).
Net sales grew organically by 6.0%.
- The gross margin increased to 43.0% (41.1).
- Adjusted EBITDA increased to SEK 523 M (436).
- Adjusted operating profit increased to SEK 247 M (165).
- Profit after financial items amounted to SEK 104 M (111).
- Earnings per share before and after dilution amounted to SEK 0.21 (0.30).
- Cash flow from operations rose to SEK 485 M (446), corresponding to a cash conversion of 100.4% (105.0).
- A revaluation of the holdings in Atlas Mobility and Veplas of SEK 62 M was charged to net financial items.
- New segment reporting based on the following: Europe, North America and International. Restated historical comparative figures are available on Arjo's website.
- Strengthening of the Arjo Management Team, read more on page 5.
- Arjo's new strategic direction was presented at the Capital Markets Day, including a commitment to improve EBIT by approximately SEK 350 M versus 2025.

"With 6% organic growth in the quarter, we continue to grow and strengthen our profitability. Our focus now is on turning our strategy into results and gradually building a stronger Arjo for the future."

ANDRÉAS ELGAARD
PRESIDENT AND CEO

Financial summary

SEK M	Quarter 3 2026	Quarter 3 2025	Jan-Sep 2026	Jan-Sep 2025	Rolling 12 months	Full-year 2025
Net sales	2,849	2,646	8,306	8,186	11,119	11,000
Gross profit	1,226	1,088	3,537	3,499	4,722	4,684
Gross margin, %	43.0	41.1	42.6	42.7	42.5	42.6
Adjusted EBITDA ¹⁾	523	436	1,462	1,396	1,987	1,922
Adjusted EBITDA margin, % ¹⁾	18.4	16.5	17.6	17.1	17.9	17.5
Adjusted EBITA ¹⁾	314	228	847	768	1,170	1,091
Adjusted EBITA margin, % ¹⁾	11.0	8.6	10.2	9.4	10.5	9.9
Operating profit (EBIT)	206	152	601	494	783	675
Adjusted operating profit (EBIT) ¹⁾	247	165	648	581	897	831
Profit after financial items	104	111	424	362	528	467
Net profit for the period	58	81	291	264	362	334
Number of shares, thousands	272,370	272,370	272,370	272,370	272,370	272,370
Earnings per share, SEK	0.21	0.30	1.07	0.97	1.33	1.23
Cash flow from operations	485	446	979	835	1,579	1,435
Cash conversion, %	100.4	105.0	69.2	63.7	82.4	79.3

1. Before exceptional items. See Alternative performance measures on page 18 and Definitions on page 21.

Solid growth and a strategy for greater value creation

We continued to perform well in the third quarter, with organic growth of 6%. While a tariff refund contributed to earnings for the quarter, the underlying profitability trend is positive, reflecting continued high demand for our products and solutions, an improved gross margin, and a continued focus on efficiency. Our ongoing evaluation of previous investments resulted in a revaluation of the holdings in Atlas Mobility and Veplas, which impacted net financial items for the quarter.

As previously announced, from the third quarter, we will report our operations in the three segments of North America, Europe and International. North America grew organically more than 6% during the quarter, and Europe more than 7%, with broad, positive performance in several markets. International performed in line with the comparative quarter, with continued solid sales growth in countries including Australia and India.

We continue to grow in a market with strong long-term drivers. An aging population, growing healthcare needs and a continued shortage of healthcare staff are increasing the need for solutions that improve safety, efficiency and quality in healthcare. Arjo holds a strong position in this area, with close customer relationships and a broad offering.

A strategy for a stronger Arjo

We presented our new strategic direction at our Capital Markets Day in September. We will strengthen our performance by focusing on our core strengths, becoming more customer-focused, streamlining the operations and using our resources more efficiently. The intention is to build a stronger Arjo today, while creating better conditions for profitable growth in the future from a more scalable base.

As a first step, we have committed to improving EBIT by approximately SEK 350 M versus 2025. This improvement will be driven mainly by a more effective operating model and enhanced procurement focus, and is not dependent on future growth. The improvement in profitability comes from

measures within existing operations and applies regardless of whether it is based on reported or adjusted EBIT. Impact is expected to increase gradually from 2027, with most effects realized in 2028 and full impact achieved by mid-2029. The implementation is expected to result in restructuring costs of approximately SEK 370 M, primarily over the next 18 months.

The EBIT improvement is the first tangible step in implementing the strategy and shows the expected impact of the measures presented. At the same time, we continue to work on several strategic initiatives and will present updated financial targets for growth, profitability and capital efficiency during the first quarter of 2027.

Focus on customers and implementation

Arjo's potential is particularly clear when we work closely with our customers and make use of the full breadth of our offering. During the quarter, we entered into a strategic partnership with a major elderly care provider in Australia. By combining the Arjo Insight analysis tool with clinical expertise, training and products from various parts of our offering, we can help improve care outcomes and the work environment, while making more efficient use of resources. This partnership is a good example of how close customer relationships and a broader perspective can create greater value for both our customers and Arjo.

We continued to strengthen the Arjo Management Team during the quarter. The aim is to increase our customer focus, improve how we collaborate to develop our offering and accelerate the pace of change in our ambition to modernize Arjo. We have an important task ahead of us. We presented our strategic direction and priorities at the Capital Markets Day. Together, we will now step by step deliver on what we have promised. From 2027, we will continuously report on progress and the results we deliver.

ANDRÉAS ELGAARD
PRESIDENT & CEO



Solid organic growth

6.0%

Group performance

Net sales per segment

SEK M	Quarter 3 2026	Quarter 3 2025 ¹⁾	Organic change	Jan-Sep 2026	Jan-Sep 2025 ¹⁾	Organic change	Rolling 12 months	Full-year 2025 ¹⁾
Europe	1,348	1,248	7.4%	3,907	3,801	4.9%	5,278	5,172
North America	1,087	1,006	6.4%	3,207	3,286	3.2%	4,280	4,359
International	414	392	0.5%	1,192	1,099	9.3%	1,561	1,469
Total	2,849	2,646	6.0%	8,306	8,186	4.8%	11,119	11,000

1. The figures for 2025 have been restated following a new segment reporting.

Net sales and results

Third quarter of 2026

Net sales for the quarter amounted to SEK 2,849 M (2,646), corresponding to an organic increase of 6.0%.

Sales in North America increased organically by 6.4%. The US grew by more than 7% organically, driven by a positive trend in patient handling, service and diagnostics. Sales in Canada also performed well during the quarter.

Sales in Europe increased organically by 7.4%, driven by healthy demand in rental solutions and service. Countries such as France, Italy, Poland, and the Netherlands performed well, while sales were slightly weaker in the UK.

International performed in line with the comparative quarter, with continued solid sales growth in countries such as Australia and India.

The gross margin increased to 43.0% (41.1). Positive mix effects offset higher material and transportation costs, while tariffs had a positive impact of approximately 1.6 percentage points on the gross margin. Adjusted for US tariff refund of approximately SEK 35 M and a SEK 11 M decrease in tariff costs, the gross margin improved slightly year on year.

Operating expenses for the quarter increased slightly to SEK 984 M (925), primarily due to higher variable selling expenses.

Exceptional items amounted to SEK 41 M (13) and relates to costs for the completed strategic review and restructuring costs attributable to activities to enhance efficiency in the Group's sales organization.

Adjusted EBITDA increased to SEK 523 M (436) and the adjusted EBITDA margin increased to 18.4% (16.5).

Operating profit amounted to SEK 206 M (152) and adjusted operating profit to SEK 247 M (165).

Net financial items for the quarter amounted to SEK -102 M (-41). A revaluation of Arjo's holdings in Atlas Mobility and Veplas of SEK 62 M was charged to net financial items. The revaluation reflects a change to the assessment of the value of the holdings and means that both holdings are now valued at zero. Positive currency effects in net financial items amounted to SEK 6 M (2) for the quarter.

Profit before tax amounted to SEK 104 M (111). Tax expense for the period amounted to SEK 46 M (30). The effective tax rate increased as a result of the revaluations described above. Net profit for the period amounted to SEK 58 M (81) and earnings per share amounted to SEK 0.21 (0.30).

January–September 2026

Net sales for the period amounted to SEK 8,306 M (8,186), corresponding to an organic increase of 4.8%.

Organic growth in North America was 3.2%, with a favorable sales trend in capital goods and service. The US performed positively, while Canada saw a slight decline in relation to a strong comparative period last year.

Sales in Europe increased organically by 4.9%. Demand was healthy in several European markets such as France, Italy and Poland.

International grew by 9.3% organically during the period, driven by a solid performance in markets including India, South Africa, Australia and New Zealand.

The gross margin was in line with the comparative period year at 42.6% (42.7).

Operating expenses for the period amounted to SEK 2,901 M (2,885).

Adjusted EBITDA for the period amounted to SEK 1,462 M (1,396).

The adjusted EBITDA margin was 17.6% (17.1).

Operating profit amounted to SEK 601 M (494) and adjusted operating profit to SEK 648 M (581).

Net financial items amounted to SEK -177 M (-132) for the period.

A revaluation of Arjo's holdings in Atlas Mobility and Veplas of SEK 62 M was charged to net financial items. Positive currency effects in net financial items amounted to SEK 23 M (9) for the period.

Profit before tax increased to SEK 424 M (362). Tax expense for the period amounted to SEK 132 M (98). The effective tax rate increased as a result of the revaluations described above. Net profit for the period amounted to SEK 291 M (264) and earnings per share amounted to SEK 1.07 (0.97).

Currency effects

SEK M	Quarter 3 2026	Jan-Sep 2026
Translation effect (vs 2025)		
Sales	+39	-284
Cost of goods sold	-25	+172
Gross profit	+15	-112
Operating expenses	-10	+80
Restructuring and other operating income/expenses	+0	+1
Total translation effect, EBIT	+5	-30
Transaction effect (vs 2025)		
Cost of goods sold	+2	-17
Recognized remeasurement effects		
Other operating income/expenses	+4	+3

Translation effects for the quarter amounted to SEK +5 M and transaction effects to SEK +2 M. In addition, the recognized revaluation effects of operating receivables and liabilities amounted to SEK +4 M for the quarter.

Cash flow and financial position

Cash flow from operations amounted to SEK 485 M (446) for the quarter. The positive cash flow from working capital was SEK 67 M (83). Cash conversion for the quarter was 100.4% (105.0).

Net investments for the quarter amounted to SEK 177 M (142), divided between tangible assets of SEK 108 M (76) and intangible assets of SEK 69 M (67). The investments in tangible assets include investments in the rental fleet of SEK 76 M (48).

The Group's cash and cash equivalents amounted to SEK 858 M (705) and interest-bearing net debt was SEK 4,240 M (4,500). Arjo has contracted unutilized credit facilities of SEK 2,799 M (4,724) available for refinancing outstanding commercial paper. The equity/assets ratio amounted to 50.3% (49.5). Net debt/adjusted EBITDA was 2.2 (2.2).

Research and development

Arjo's gross research and development costs for the quarter amounted to SEK 68 M (67), of which SEK 35 M (34) was charged to operating profit, see also Note 4. The gross costs correspond to 2.4% (2.5) of consolidated net sales.

Outlook 2026

Organic sales growth for 2026 is expected to be within the Group's target interval of 3-5%.

Other information

Nomination Committee ahead of 2027 Annual General Meeting

In accordance with the resolution of Arjo's 2020 Annual General Meeting, the Nomination Committee in respect of the Annual General Meeting shall be composed of members appointed by the three largest shareholders in terms of voting rights, based on a list of owner-registered shareholders from Euroclear Sweden AB or other reliable ownership information, as of August 31 of each year, and the Chairman of the Board of Directors. In addition, if the Chairman of the Board, in consultation with the member appointed by the largest shareholder in terms of voting rights, deems it appropriate, it shall include an, in relation to the company and its major shareholders, independent representative of the minor shareholders as a member of the Nomination Committee.

Ahead of the 2027 Annual General Meeting, Arjo's Nomination Committee comprised Chairman Carl Bennet (Carl Bennet AB), Anna Magnusson (Fourth Swedish National Pension Fund), Anders Oscarsson (Svolder), as well as Board Chairman Johan Malmquist.

Shareholders who would like to submit proposals to Arjo's Nomination Committee ahead of the 2027 Annual General Meeting can contact the Nomination Committee by e-mail at nominating.committee@arjo.com or by mail: Arjo AB, Att: Nomination Committee, Hans Michelsensgatan 10, SE-211 20 Malmö, Sweden. The deadline for submitting a proposal to the Nomination Committee is December 31, 2026.

2027 Annual General Meeting

Arjo's Annual General Meeting will be held on April 19, 2027 in Malmö, Sweden. Shareholders wishing to have a matter addressed at the AGM can submit their proposal to Arjo's Board Chairman by e-mail: agm@arjo.com, or by mail: Arjo AB, Att: Bolagsstämmoörenden, Hans Michelsensgatan 10, SE-211 20 Malmö, Sweden. To ensure inclusion in the notice and thus in the Annual General Meeting's agenda, proposals must be received by the company by March 1, 2027.


Transactions with related parties

Transactions between Arjo and companies in Getinge Group are specified in Note 10.

Forward-looking information

This report contains forward-looking information based on the current expectations of Arjo's Management Team. Although management considers the expectations presented by such forward-looking information to be reasonable, there is no guarantee that these expectations will prove correct. Consequently, actual outcomes may vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding the economy, market and competition, changes in legal and regulatory requirements, as well as other policy measures and fluctuations in exchange rates.

Capital Markets Day 2026



OUR STARTING POINT

A diversified revenue base across categories and geographies

PERCENTAGE OF TOTAL REVENUE BY CATEGORY

27%

Patient handling

16%

Medical beds

16%

Pressure injury prevention

7%

Hygiene

3%

Diagnostics

3%

Diagnostics

20%

Service



SALES BY GEOGRAPHY

Europe, 41%

North America, 37%

Other, 22%



SALES BY GEOGRAPHY

Europe, 41%

North America, 37%

Other, 22%

Other events

New strategy and improved profitability

At the Capital Markets Day in September, Arjo presented a new strategy to strengthen performance by focusing on core strengths, becoming more customer-centric, streamlining operations and using resources more efficiently. The strategy is intended to build a stronger Arjo today, while creating better conditions for profitable growth in the future from a more scalable base.

As a first step Arjo is committed to improving EBIT by approximately SEK 350 M versus 2025. The improvement will be driven mainly by a more effective operating model and enhanced procurement focus, and is not dependent on future growth. The improvement in profitability comes from measures within existing operations and applies regardless of whether it is based on reported or adjusted EBIT. The earnings effects are expected to increase gradually from 2027, with most effects realized in 2028 and the full effect achieved by mid-2029. The implementation is expected to result in restructuring costs of approximately SEK 370 M, primarily over the next 18 months.

The EBIT improvement is the first tangible step in implementing the strategy and outlines the expected impact of the measures presented. At the same time, Arjo is continuing to carry out several strategic initiatives and will present updated financial targets for growth, profitability and capital efficiency during the first quarter of 2027.

New segment reporting

During the quarter, Arjo introduced a new segment reporting structure based on three geographic segments. The new segment reporting structure is intended to provide investors with a more relevant and useful overview of Arjo's business by bringing together financially and commercially similar markets into the three reportable segments: Europe, North America and International. The change also reflects Arjo's ongoing transformation journey and its new operating model, with greater collaboration and a more integrated way of working between markets within each respective segment.

To ensure comparability with historical periods, restated historical comparative figures for the 2024 and 2025 fiscal years and the last ten quarters (Q1 2024-Q2 2026) are available on Arjo's website. The restatement does not affect Arjo's previously recognized total sales or earnings.

Changes to the Arjo Management Team

During the quarter, Martin Waldén assumed the position of Executive Vice President of the new Group function, Group Sales & Group Transformation. The function will be responsible for driving Arjo's transformation agenda and developing its commercial capabilities. Martin Waldén has extensive experience in strategic and commercial change management from senior roles at PwC and Accenture Strategy Consulting, and from commercial and strategic line management positions. He took up his role on August 1.

As previously announced, Arjo has also appointed Lisa Ekelund as its new CFO. Lisa Ekelund has extensive international experience from senior finance and business leadership positions. She most recently served as CFO of Polestar Nordics, and was previously Vice President and CFO at Saab Surveillance and held several senior finance leadership positions in Volvo Group. Lisa will take office in early November and succeed Christofer Carlsson, who will leave Arjo by the end of January 2027.

Moreover, Arjo has established a new Group function called Group Portfolio. This function will assume overall responsibility for product strategy, portfolio management, innovation and product development, with the aim of sharpening priorities, strengthening execution and improving capabilities to develop and launch competitive solutions. The function will be led by Jennie Borgström, who has been appointed Executive Vice President, Group Portfolio, and a member of the Arjo Management Team, effective November 1. Jennie Borgström has extensive international experience from senior positions at Alfa Laval. In connection with this change, Tobias Kramer, Executive Vice President Global Marketing, has decided to leave Arjo.



Risk management at Arjo

Arjo sells products and services through its own companies and distributors to customers in more than 100 countries. The Group has suppliers of direct materials in more than 50 countries and production in five countries. The company is thus exposed to a number of strategic, operational, financial and regulatory risks, and risk management is a natural element of day-to-day operations.

The company's risks are identified and evaluated under the framework of Arjo's Enterprise Risk Management (ERM) process. Managing and preventing risks are important aspects of Arjo's strategic planning process and internal control process, and encompass all business areas and Group functions. Identified risks are continuously evaluated and measures are taken to mitigate potential negative effects. The results of risk management activities are regularly reported to the Management Team and the Board.

Arjo's long-term risks that are deemed to have the greatest impact on its operations include changes in healthcare reimbursement systems and regulatory requirements, product quality and product safety, research and development, cybersecurity and information security and risks in the value chain.

For more information about the long-term risks related to Arjo, as well as the Group's risk exposure and risk management, refer to the 2025 Annual Report, which is available at www.arjo.com.



Assurance

The Board of Directors and CEO assure that the interim report provides a true and fair review of the Parent Company and the Group's operations, position and earnings and describes the material risks and uncertainties faced by the Parent Company and the Group.

Malmö, October 22, 2026

Johan Malmquist
Chairman of
the Board

Carl Bennet
Vice Chairman
of the Board

Ulrika Dellby
Board member

Eva Elmstedt
Board member

Dan Frohm
Board member

Ulf Grunander
Board member

Carola Lemne
Board member

Andréas Elgaard
President & CEO

Madeléne Carlsson
Board member
Employee representative

Kajsa Haraldsson
Board member
Employee representative

Review report

Arjo AB (publ) Corp.reg.no 559092-8064

To the Board of Directors of Arjo AB (publ)

Introduction

We have reviewed the condensed interim report of Arjo AB (publ) as of September 30, 2026 and the nine months period that ended. The board of Directors and the Managing Director are responsible for the preparation and presentation of this interim report in accordance with IAS 34 and the Swedish Annual Accounts Act. Our responsibility is to express a conclusion on this interim report based on our review.

Scope of review

We conducted our review in accordance with the International Standard on Review Engagements, ISRE 2410 *Review of Interim Report Performed by the Independent Auditor of the Entity*. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and other generally accepted auditing standards in Sweden. The procedures performed in a review do not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the interim report is not prepared, in all material respects, in accordance with IAS 34 and the Swedish Annual Accounts Act regarding the Group, and in accordance with the Swedish Annual Accounts Act regarding the Parent Company.

Malmö, October 22, 2026

Ernst & Young AB

Karoline Tedevall
Authorized Public Accountant

Consolidated financial statements

CONDENSED CONSOLIDATED INCOME STATEMENT

SEK M	Note	Quarter 3 2026	Quarter 3 2025	Jan - Sep 2026	Jan - Sep 2025	Full-year 2025
Net sales	2	2,849	2,646	8,306	8,186	11,000
Cost of goods sold		-1,624	-1,558	-4,769	-4,687	-6,315
Gross profit		1,226	1,088	3,537	3,499	4,684
Selling expenses		-562	-536	-1,667	-1,669	-2,211
Administrative expenses		-387	-355	-1,127	-1,105	-1,463
Research and development costs	4	-35	-34	-107	-112	-140
Exceptional items	5	-41	-13	-47	-87	-155
Other operating income		4	7	14	10	12
Other operating expenses		0	-5	-2	-42	-52
Operating profit (EBIT)	3	206	152	601	494	675
Net financial items	6	-102	-41	-177	-132	-209
Profit after financial items		104	111	424	362	467
Taxes		-46	-30	-132	-98	-132
Net Profit for the period		58	81	291	264	334
Attributable to:						
Parent Company shareholders		58	81	291	264	334
Number of shares, thousands		272,370	272,370	272,370	272,370	272,370
Earnings per share, SEK ¹⁾		0.21	0.30	1.07	0.97	1.23

1. Before and after dilution. For definition, see page 21.

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

SEK M	Quarter 3 2026	Quarter 3 2025	Jan - Sep 2026	Jan - Sep 2025	Full-year 2025
Net profit for the period	58	81	291	264	334
Other comprehensive income					
Items that cannot be restated in profit					
Actuarial gains/losses pertaining to defined-benefit pension plans	-37	9	-7	-3	-2
Tax attributable to items that cannot be restated in profit	9	-3	2	22	20
Items that can later be restated in profit					
Translation differences	222	-129	550	-956	-1,131
Hedges of net investments	-1	9	3	67	101
Cash-flow hedges	45	7	39	1	8
Tax attributable to items that can be restated in profit	-26	7	-48	43	48
Other comprehensive income for the period, net after tax	213	-98	539	-825	-957
Total comprehensive income for the period	271	-17	831	-561	-622
Comprehensive income attributable to:					
Parent Company shareholders	271	-17	831	-561	-622

CONDENSED CONSOLIDATED BALANCE SHEET

SEK M	Note	Sep 30, 2026	Sep 30, 2025	Dec 31, 2025
Assets				
Intangible assets		7,469	7,295	7,215
Tangible assets		1,586	1,539	1,486
Tangible lease assets		1,229	1,131	1,214
Financial assets	7	828	847	739
Total non-current assets		11,112	10,813	10,654
Inventories		1,415	1,353	1,177
Accounts receivable		1,888	1,656	1,617
Current financial receivables	7	23	28	27
Other current receivables		526	513	548
Cash and cash equivalents	7	858	705	836
Assets held for sale		129	122	119
Total current assets		4,840	4,377	4,323
Total assets		15,953	15,190	14,977
Shareholders' equity and liabilities				
Shareholders' equity		8,029	7,519	7,457
Equity attributable to the Parent Company		8,029	7,519	7,457
Non-current financial liabilities	7	2,642	2,976	2,637
Non-current lease liabilities	7	882	779	858
Provisions for pensions, interest-bearing	7	36	35	34
Other provisions, non-current		281	224	229
Total non-current liabilities		3,840	4,013	3,757
Other provisions, current		58	55	56
Current financial liabilities	7	1,418	1,317	1,450
Current lease liabilities	7	412	403	408
Accounts payable		615	505	508
Other non-interest-bearing liabilities		1,581	1,378	1,339
Total current liabilities		4,083	3,657	3,762
Total shareholders' equity and liabilities		15,953	15,190	14,977

CONDENSED CHANGES IN SHAREHOLDERS' EQUITY FOR THE GROUP

SEK M	Share Capital	Reserves	Retained earnings	Total shareholders' equity ¹⁾
Opening balance at January 1, 2025	91	1,807	6,440	8,338
Net profit for the period	-	-	334	334
Other comprehensive income for the period, net after tax	-	-975	18	-957
Total comprehensive income for the period	-	-975	352	-622
Dividend	-	-	-259	-259
Closing balance at December 31, 2025	91	832	6,534	7,457
Opening balance at January 1, 2026	91	832	6,534	7,457
Net profit for the period	-	-	291	291
Other comprehensive income for the period, net after tax	-	544	-5	539
Total comprehensive income for the period	-	544	286	831
Dividend	-	-	-259	-259
Closing balance at September 30, 2026	91	1,377	6,562	8,029

1. Fully attributable to Parent Company shareholders.

CONDENSED CONSOLIDATED CASH-FLOW STATEMENT

SEK M	Note	Quarter 3 2026	Quarter 3 2025	Jan - Sep 2026	Jan - Sep 2025	Full-year 2025
Operating activities						
Operating profit (EBIT)		206	152	601	494	675
Add-back of amortization, depreciation and write-down	3	277	273	813	817	1,136
Other non-cash items		19	23	20	-8	-15
Expensed exceptional items ¹⁾		41	11	47	85	109
Paid exceptional items		-45	-23	-57	-80	-105
Financial items		-40	-36	-128	-137	-177
Taxes paid		-40	-37	-121	-151	-208
Cash flow before changes to working capital		418	363	1,176	1,020	1,415
Changes in working capital						
Inventories		-82	-12	-161	-94	77
Current receivables		1	98	-211	9	13
Current liabilities		148	-3	174	-99	-70
Cash flow from operations		485	446	979	835	1,435
Investing activities						
Acquired operations	11	-	-5	-30	-8	-27
Net investments		-177	-142	-476	-526	-678
Cash flow from investing activities		-177	-148	-506	-534	-705
Financing activities						
Raising of loans		1,112	3,274	5,150	15,930	19,736
Repayment of financial liabilities		-1,336	-3,490	-5,179	-15,705	-19,687
Repayment of lease liabilities		-109	-121	-326	-343	-449
Change in pension assets/liabilities		-1	-4	-4	-7	-8
Change in interest-bearing receivables		8	7	12	46	49
Dividend		-	-	-259	-259	-259
Realized derivatives attributable to financing activities		64	-20	79	-112	-113
Cash flow from financing activities		-262	-354	-528	-449	-730
Cash flow for the period		46	-56	-55	-147	0
Cash and cash equivalents at the beginning of the period		818	766	836	892	892
Translation differences		-6	-5	77	-39	-56
Cash and cash equivalents at the end of the period		858	705	858	705	836

1. Excluding write-down of non-current assets.

1 Accounting policies

The Group's interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the applicable rules of Swedish Annual Accounts Act. The Parent Company has prepared the interim report in accordance with the Swedish Annual Accounts Act (1995:1554) and the Swedish Sustainability and Financial Reporting Board's recommendation RFR 2, Accounting for Legal Entities.

The accounting policies applied in the preparation of this interim report apply to all periods and are consistent with the accounting policies presented in the 2025 Annual Report, published on www.arjo.com. No new or changed accounting standards that came into effect on January 1, 2026 had a material impact on Arjo. Arjo has decided not to apply in advance new standards, amendments or interpretations that have been published but will not come into effect until the fiscal year beginning on or after January 1, 2027.

IFRS 18 Presentation and Disclosure in Financial Statements will be applied by the Arjo Group from January 1, 2027. Arjo is currently assessing the impact that the standard will have on the Group's financial

reporting. The standard is expected primarily to affect presentation of the statement of profit or loss, including the classification of income and expenses within the operating, investing and financing categories, as well as the introduction of new subtotals. The standard is not expected to affect the Group's reported profit. IFRS 18 also introduces enhanced disclosure requirements relating to Management Performance Measures. Arjo is currently assessing which performance measures fall within the scope of the definition and how these measures should be presented.

The totals in the tables and calculations do not always add up due to rounding differences. Each subtotal corresponds with its original source, which can lead to rounding differences in the totals.

The holding in Bruin Biometrics LLC (BBI) has been classified as an asset held for sale since the fourth quarter of 2024. Due to circumstances beyond Arjo's control, the sales process has taken longer than expected. Based on the current status of the sales process and Arjo's continued intention to divest the holding, the classification is considered to remain as of the balance sheet date.

2 Segment reporting

SEK M	Quarter 3 2026					Quarter 3 2025 ¹⁾				
	Europe	North America	Inter-national	Group functions	Arjo Group	Europe	North America	Inter-national	Group functions	Arjo Group
Product sales	648	658	274	-	1,580	573	605	267	-	1,445
Service incl. spare parts	327	185	74	-	585	317	166	68	-	551
Revenue from contracts with customers	975	843	348	-	2,166	890	771	335	-	1,996
Rental	373	244	66	-	684	358	235	57	-	650
Total net sales	1,348	1,087	414	-	2,849	1,248	1,006	392	-	2,646
Operating profit/loss	232	257	51	-334	206	164	200	63	-275	152
Net financial items					-102					-41
Profit after financial items					104					111
Taxes					-46					-30
Net profit for the period					58					81

SEK M	Jan - Sep 2026					Jan - Sep 2025 ¹⁾				
	Europe	North America	Inter-national	Group functions	Arjo Group	Europe	North America	Inter-national	Group functions	Arjo Group
Product sales	1,852	1,961	795	-	4,608	1,753	1,987	727	-	4,468
Service incl. spare parts	954	521	210	-	1,685	946	520	191	-	1,657
Revenue from contracts with customers	2,807	2,482	1,005	-	6,294	2,699	2,508	918	-	6,125
Rental	1,100	725	187	-	2,012	1,102	778	181	-	2,061
Total net sales	3,907	3,207	1,192	-	8,306	3,801	3,286	1,099	-	8,186
Operating profit/loss	621	770	173	-962	601	556	747	127	-936	494
Net financial items					-177					-132
Profit after financial items					424					362
Taxes					-132					-98
Net profit for the period					291					264

1. The segment reporting for 2025 has been restated as described below.

Segment reporting, cont.

SEK M	Full-year 2025 ¹⁾				
	Europe	North America	Inter-national	Group functions	Arjo Group
Product sales	2,419	2,644	970	-	6,033
Service incl. spare parts	1,280	689	261	-	2,229
Revenue from contracts with customers	3,699	3,333	1,230	-	8,262
Rental	1,473	1,026	239	-	2,737
Total net sales	5,172	4,359	1,469	-	11,000
Operating profit/loss	810	960	176	-1,271	675
Net financial items					-209
Profit after financial items					467
Taxes					-132
Net profit for the period					334

1. The segment reporting for 2025 has been restated as described below.

Arjo monitors its operations within the segments Europe, North America and International (includes distributor markets in Eastern Europe). The segment structure was revised in the third quarter of 2026 as a result of Arjo's new strategic direction. Comparative figures have been restated to reflect the new segment reporting structure. Restated historical quarterly data for the period from the first quarter of 2024 to the second quarter of 2026 are available on the Company's website www.arjo.com. The principles for measuring segment results remain consistent with

those applied in the 2025 Annual Report. Arjo has significant central Group functions in the areas of Supply Chain (product supply, inventory, and distribution), IT, Quality, and Research and Development. Costs of goods sold within the Supply Chain are allocated to each segment. The remaining expenses for the Group functions are recognized as Group expenses. Assets and liabilities are not divided by segment since no such amounts are regularly reported to the chief operating decision maker.

3 Depreciation/amortization and write-down

SEK M	Quarter 3 2026	Quarter 3 2025	Jan - Sep 2026	Jan - Sep 2025	Full-year 2025
Intangible assets	-67	-63	-199	-187	-296
<i>Of which, attributable to acquisitions</i>	-18	-17	-52	-53	-70
Tangible assets	-97	-99	-281	-298	-399
Tangible lease assets	-113	-111	-333	-332	-441
Total	-277	-273	-813	-817	-1,136
<i>Of which, write-down</i>	-	-2	-	-2	-44

Depreciation/amortization and write-downs by function, SEK M	Quarter 3 2026	Quarter 3 2025	Jan - Sep 2026	Jan - Sep 2025	Full-year 2025
Cost of goods sold	-184	-181	-538	-543	-722
Selling expenses	-44	-41	-128	-125	-170
Administrative expenses	-47	-47	-143	-142	-192
Research and development costs	-2	-2	-5	-5	-7
Exceptional items	-	-2	-	-2	-44
Total	-277	-273	-813	-817	-1,136
<i>Of which, write-down</i>	-	-2	-	-2	-44

4 Research and development costs

SEK M	Quarter 3 2026	Quarter 3 2025	Jan - Sep 2026	Jan - Sep 2025	Full-year 2025
Research and development costs, gross	-68	-67	-214	-234	-303
Capitalized development costs	33	33	108	122	163
Research and development costs, net	-35	-34	-107	-112	-140

5 Exceptional items

SEK M	Quarter 3 2026	Quarter 3 2025	Jan - Sep 2026	Jan - Sep 2025	Full-year 2025
Acquisition expenses	-	0	0	-1	-2
Impairment of ERP system	-	-	-	-	-35
Restructuring and integration costs ¹⁾	-41	-13	-47	-86	-118
Total	-41	-13	-47	-87	-155

1. The amount for 2026 relates to costs associated with the completed strategic review, as well as restructuring costs related to activities to improve the efficiency of the Group's sales organization.

Exceptional items by function, SEK M	Quarter 3 2026	Quarter 3 2025	Jan - Sep 2026	Jan - Sep 2025	Full-year 2025
Cost of goods sold	-2	-3	-2	-34	-46
Selling expenses	-3	-2	-5	-10	-20
Administrative expenses	-36	-6	-37	-40	-86
Research and development costs	-	-1	-2	-1	-1
Other operating expenses	0	0	0	-2	-2
Total	-41	-13	-47	-87	-155

The table above presents the function in which the items would have been recognized had they not been classified as exceptional items.

6 Financial assets and liabilities measured at fair value

	Assets/liabilities measured at fair value through profit or loss	Derivatives used for hedging purposes	Total
Sep 30, 2026, SEK M			
Other current receivables, derivatives	1	-	1
Other financial assets ¹⁾	1	45	47
Total assets	2	45	47
Other non-interest-bearing liabilities, derivatives	7	-	7
Total liabilities	7	-	7

	Assets/liabilities measured at fair value through profit or loss	Derivatives used for hedging purposes	Total
Sep 30, 2025, SEK M			
Other current receivables, derivatives	8	-	8
Other financial assets	98	-	98
Total assets	107	-	107
Other non-interest-bearing liabilities, derivatives	6	1	7
Total liabilities	6	1	7

	Assets/liabilities measured at fair value through profit or loss	Derivatives used for hedging purposes	Total
Dec 31, 2025, SEK M			
Other current receivables, derivatives	4	-	4
Other financial assets ¹⁾	63	6	69
Total assets	67	6	73
Other non-interest-bearing liabilities, derivatives	3	-	3
Total liabilities	3	-	3

1. During the quarter, other non-current financial assets were remeasured by SEK -62 M. During the fourth quarter of 2025, they were remeasured by SEK -35 M.

For a description of valuation techniques and inputs used in the valuation, please refer to Note 28 in the Annual Report for 2025. For other financial assets and liabilities in the Group, the reported values represent a reasonable approximation of their fair values.

7 Consolidated interest-bearing net debt

SEK M	Sep 30, 2026	Sep 30, 2025	Dec 31, 2025
Non-current financial liabilities	2,642	2,976	2,637
Non-current lease liabilities	882	779	858
Current financial liabilities	1,418	1,317	1,450
Current lease liabilities	412	403	408
Provisions for pensions	36	35	34
Interest-bearing liabilities	5,389	5,510	5,387
Less financial receivables	-65	-90	-82
Less pension assets	-227	-213	-214
Less cash and cash equivalents	-858	-705	-836
Interest-bearing net debt	4,240	4,500	4,255

8 Key figures for the Group

SEK M	Quarter 3 2026	Quarter 3 2025	Jan - Sep 2026	Jan - Sep 2025	Full-year 2025
Sales measures					
Net sales	2,849	2,646	8,306	8,186	11,000
Net sales growth, %	7.7	-3.2	1.5	-1.4	-2.6
Organic growth in sales, %	6.0	3.8	4.8	3.4	3.4
Expense measures					
Selling expenses as a % of net sales	19.7	20.2	20.1	20.4	20.1
Administrative expenses as a % of net sales	13.6	13.4	13.6	13.5	13.3
Research and development costs gross as a % of net sales	2.4	2.5	2.6	2.9	2.8
Earnings measures					
EBITDA	483	425	1,415	1,311	1,811
EBITDA growth, %	13.7	-0.9	7.9	-6.0	-8.4
Adjusted EBITDA ¹⁾	523	436	1,462	1,396	1,922
EBITA	273	215	800	681	971
Adjusted EBITA ¹⁾	314	228	847	768	1,091
Operating profit (EBIT)	206	152	601	494	675
Adjusted operating profit (EBIT) ¹⁾	247	165	648	581	831
Earnings per share, SEK	0.21	0.30	1.07	0.97	1.23
Margin measures					
Gross margin, %	43.0	41.1	42.6	42.7	42.6
EBITDA margin, %	16.9	16.0	17.0	16.0	16.5
Adjusted EBITDA margin, % ¹⁾	18.4	16.5	17.6	17.1	17.5
EBITA margin, %	9.6	8.1	9.6	8.3	8.8
Adjusted EBITA margin, % ¹⁾	11.0	8.6	10.2	9.4	9.9
Operating margin, %	7.2	5.7	7.2	6.0	6.1
Adjusted Operating margin, % ¹⁾	8.7	6.2	7.8	7.1	7.6
Cash flow and return measures					
Return on shareholders' equity, % ²⁾			4.7	5.7	4.2
Cash Conversion, %	100.4	105.0	69.2	63.7	79.3
Operating Capital			12,442	12,457	12,456
Return on operating capital, % ²⁾			7.2	7.7	6.7
Capital Structure					
Interest-bearing net debt			4,240	4,500	4,255
Interest-coverage ratio, multiple ²⁾			4.2	4.7	4.0
Net debt/equity ratio, multiple			0.5	0.6	0.6
Net debt/adjusted EBITDA, multiple ^{1, 2)}			2.2	2.2	2.2
Equity/asset ratio, %			50.3	49.5	49.8
Equity per share, SEK			29.5	27.6	27.4
Other					
Number of shares			272,369,573	272,369,573	272,369,573
Number of employees, average ²⁾			6,936	6,996	6,942

1. Before exceptional items. See Alternative performance measures on page 18 and definitions on page 21.

2. Rolling 12 months.

ALTERNATIVE PERFORMANCE MEASURES

Alternative performance measures refer to financial measures used by the company's management and investors to evaluate the Group's earnings and financial position, and that cannot be directly read or derived from the financial statements. These financial measures are intended to facilitate analysis of the Group's performance. The alternative performance measures should not be considered substitutes, but rather a

supplement to, the financial statements prepared in accordance with IFRS. The financial measures recognized in this report may differ from similar measures used by other companies. The alternative performance measures presented below have not been calculated in accordance with IFRS but are provided because Arjo considers them important to investors' assessment of the Company and its share.

Adjusted EBITDA/EBITA/EBIT SEK M	Quarter 3 2026	Quarter 3 2025	Jan - Sep 2026	Jan - Sep 2025	Full-year 2025
EBITDA	483	425	1,415	1,311	1,811
Depreciation and impairment of tangible assets	-210	-209	-615	-630	-840
EBITA	273	215	800	681	971
Amortization and write-down of intangible assets	-67	-63	-199	-187	-296
Operating profit (EBIT)	206	152	601	494	675
Exceptional items ¹⁾	41	13	47	87	155
Add-back of write-down of exceptional items	-	-2	-	-2	-44
Adjusted EBITDA	523	436	1,462	1,396	1,922
Adjusted EBITA	314	228	847	768	1,091
Adjusted operating profit (EBIT)	247	165	648	581	831

Cash conversion	Quarter 3 2026	Quarter 3 2025	Jan - Sep 2026	Jan - Sep 2025	Full-year 2025
Cash flow from operations, SEK M	485	446	979	835	1,435
Operating profit (EBIT), SEK M	206	152	601	494	675
Add-back of amortization and write-down of intangible assets and tangible assets, SEK M	277	273	813	817	1,136
EBITDA, SEK M	483	425	1,415	1,311	1,811
Cash conversion, %	100.4	105.0	69.2	63.7	79.3

Net debt/equity ratio	Sep 30, 2026	Sep 30, 2025	Dec 31, 2025
Interest-bearing net debt, SEK M	4,240	4,500	4,255
Shareholders' equity, SEK M	8,029	7,519	7,457
Net debt/equity ratio, multiple	0.5	0.6	0.6

Calculation of return on operating capital	Jan - Sep 2026	Jan - Sep 2025	Full-year 2025
Total assets opening balance, SEK M	15,190	15,677	16,276
Total assets closing balance, SEK M	15,953	15,190	14,977
Average total assets, SEK M	15,571	15,433	15,626
Average total assets, SEK M	15,571	15,433	15,626
Excluding average cash and cash equivalents, SEK M	-782	-712	-864
Excluding average other provisions, SEK M	-309	-265	-317
Excluding average other non-interest-bearing liabilities, SEK M	-2,039	-2,000	-1,990
Average operating capital, SEK M	12,442	12,457	12,456
Operating profit (EBIT), SEK M ²⁾	783	781	675
Add-back of exceptional items, SEK M ²⁾	115	176	155
EBIT after add-back of exceptional items, SEK M	897	956	831
Return on operating capital, %	7.2	7.7	6.7

1. Refer to Note 5 Exceptional items.

2. Rolling 12 months.

9 Financial data per quarter

SEK M	Quarter 1 2025	Quarter 2 2025	Quarter 3 2025	Quarter 4 2025	Quarter 1 2026	Quarter 2 2026	Quarter 3 2026
Net sales	2,863	2,678	2,646	2,814	2,698	2,759	2,849
Cost of goods sold	-1,613	-1,516	-1,558	-1,629	-1,549	-1,596	-1,624
Gross profit	1,250	1,162	1,088	1,185	1,149	1,163	1,226
Operating expenses	-1,010	-951	-925	-928	-961	-956	-984
Exceptional items	-40	-34	-13	-68	-6	0	-41
Other operating income/expenses	-32	-3	2	-7	3	4	5
Operating profit (EBIT)	168	174	152	182	184	211	206
Net financial items	-43	-48	-41	-77	-36	-40	-102
Profit after financial items	125	126	111	104	148	171	104
Taxes	-34	-34	-30	-34	-40	-46	-46
Net Profit for the period	91	92	81	70	108	125	58
Adjusted EBITDA ¹⁾	486	475	436	526	456	482	523
Adjusted EBITDA margin, % ¹⁾	17.0	17.7	16.5	18.7	16.9	17.5	18.4

1. EBITDA before exceptional items. Refer to Note 5 Exceptional items, Alternative performance measures on page 18 and definitions on page 21.

10 Transactions with related parties

SEK M	Quarter 3 2026	Quarter 3 2025	Jan - Sep 2026	Jan - Sep 2025	Full-year 2025
Sales	5	3	16	18	23
Purchases of goods	-3	-4	-9	-9	-10
Accounts receivable	0	0	3	2	2
Accounts payable	0	0	2	1	1

Carl Bennet AB is the parent company and has a controlling influence over the Arjo Group. In addition to the customary dividend to Carl Bennet AB, Arjo has conducted transactions with companies within the Getinge Group, over which Carl Bennet AB also has a controlling influence. Arjo uses Getinge as a distributor in certain markets. Transactions involving the delivery of products and services between the groups are carried out on commercial terms and at market-based prices. Transactions with the Getinge Group are specified in the table above. Apart from the above, no other material related-party transactions have taken place.

11 Acquisitions

Acquisitions 2026

During the second quarter, Arjo acquired parts of the business of the Australian company M and D Miscevic Pty Ltd (MD Engineering Solutions), which provides service of medical devices. The purchase price amounted to SEK 30 M. The acquisition was structured as an asset deal and has been integrated into Arjo's existing operations in Australia since June 1. The acquired business generates annual sales of approximately SEK 12 M.

As the acquisition is not considered material in relation to Arjo, no further disclosures are provided in this report.

Acquisitions 2025

During the third quarter, Arjo acquired parts of the business of the Australian company Arden Maintenance Services Pty Ltd, which provides service of medical devices. The purchase price amounted to SEK 5 M. The acquisition was made as an asset deal and was integrated into Arjo's existing operations in Australia. The acquired business generates annual sales of approximately SEK 3 M.

During the fourth quarter, all shares in the three Dutch companies SlingCare B.V., SlingCare Products B.V. and Josh IP B.V., which specialize in patient handling solutions, were acquired. The purchase price amounted to SEK 19 M and annual sales amount to approximately SEK 6 M.

During the second quarter of 2025, a purchase price adjustment of SEK 2 M was recognized in relation to an acquisition completed in 2024.

Parent Company financial statements

CONDENSED PARENT COMPANY INCOME STATEMENT

SEK M	Quarter 3 2026	Quarter 3 2025	Jan - Sep 2026	Jan - Sep 2025	Full-year 2025
Net sales	-	-	-	-	320
Administrative expenses	-52	-35	-146	-112	-393
Exceptional items ¹⁾	-35	-1	-35	-33	-33
Other operating income and expenses	0	0	-2	0	-1
Operating loss (EBIT)	-87	-36	-183	-145	-107
Income from participations in Group companies	208	17	425	296	471
Net financial items ²⁾	-60	-17	-90	-56	-76
Profit after financial items	61	-36	152	95	288
Taxes	21	10	46	41	-4
Net Profit for the period³⁾	82	-26	198	135	284

1. Exceptional items refer to restructuring costs.

2. Net financial items contain interest income, interest expenses, other financial expenses and exchange-rate gains and losses attributable to the translation of financial receivables and liabilities in foreign currencies measured at the closing day rate.

3. Also comprehensive income for the period.

CONDENSED PARENT COMPANY BALANCE SHEET

SEK M	Sep 30, 2026	Sep 30, 2025	Dec 31, 2025
Assets			
Intangible assets	418	379	384
Financial assets	5,996	6,049	5,994
Non-current financial receivables, Group companies	2,000	1,000	2,000
Total non-current assets	8,413	7,428	8,377
Other current receivables, Group companies	303	184	306
Current receivables	54	48	44
Total current assets	358	232	350
Total assets	8,771	7,660	8,727
Shareholders' equity and liabilities			
Shareholders' equity	4,523	4,434	4,583
Non-current financial liabilities	2,000	1,000	2,000
Provisions, non-current	3	3	3
Total non-current liabilities	2,003	1,003	2,003
Provisions, current	-	5	4
Current financial liabilities	1,397	1,283	845
Current financial liabilities, Group companies	761	882	1,244
Other current liabilities, Group companies	12	15	14
Other non-interest-bearing liabilities	75	37	34
Total current liabilities	2,245	2,222	2,141
Total shareholders' equity and liabilities	8,771	7,660	8,727

The Parent Company's commercial paper program has a framework amount of SEK 5,000 M (5,000). The total amount issued at the end of the period amounted to SEK 1,396 M (1,285). The Parent Company's MTN program has a framework amount of SEK 5,000 M (5,000). The total amount issued at the end of the period amounted to SEK 2,000 M (1,000).

Definitions

FINANCIAL TERMS

Adjusted EBIT/Operating profit

Operating profit with add-back of exceptional items.

Adjusted EBITA

EBITA with add-back of exceptional items.

Adjusted EBITA margin

Adjusted EBITA in relation to net sales.

Adjusted EBITDA

EBITDA with add-back of exceptional items.

Adjusted EBITDA margin

Adjusted EBITDA in relation to net sales.

Cash conversion

Cash flow from operations in relation to EBITDA.

EBIT

Operating profit.

EBITA

Operating profit before amortization and write-down of intangible assets.

EBITA margin

EBITA in relation to net sales.

EBITDA

Operating profit before amortization, depreciation and write-down.

EBITDA margin

EBITDA in relation to net sales.

Exceptional items

Total of acquisition and restructuring costs as well as major non-recurring items.

Earnings per share

Profit for the period attributable to Parent Company shareholders in relation to average number of shares. The following data was used to calculate earnings per share for the period:

Profit for the period attributable to Parent Company shareholders	SEK 291 M
Number of shares, thousands	272,370
Earnings per share	SEK 1.07

Equity/assets ratio

Shareholders' equity in relation to total assets.

Interest-coverage ratio

Profit after financial items plus interest expenses and add-back of exceptional items in relation to interest expenses. Calculated based on rolling twelve-month data.

Net debt/adjusted EBITDA

Average net debt in relation to rolling 12 months' adjusted EBITDA.

Net debt/equity ratio

Interest-bearing net debt in relation to shareholders' equity.

Operating capital

Average total assets less cash and cash equivalents, other provisions, accounts payable and other non-interest-bearing liabilities.

Organic change

A financial change adjusted for currency fluctuations, acquisitions and divestments.

Operating expenses

Selling expenses, administrative expenses and research and development costs.

Operating margin

Operating profit in relation to net sales.

Return on operating capital

Rolling 12 months' operating profit with add-back of exceptional items in relation to operating capital.

Return on shareholders' equity

Rolling 12 months' profit after tax in relation to average shareholders' equity.

MEDICAL AND OTHER TERMS

Arjo Insight

Arjo's evidence-based assessment tool for identifying risks at healthcare facilities and providing a recommendation on which equipment is needed to reduce the risk of, for example, work-related injuries or a reduction in the healthcare quality.

Compression therapy

Treatment technique which means that one uses outer pressure with a certain frequency and for a certain period of time to treat and prevent venous leg ulcers.

DVT (deep vein thrombosis)

Formation of a blood clot in one of the body's deep veins, often in the leg.

Ergonomics

A science concerned with designing the job to fit the worker to prevent illness and accidents.

ESG

An abbreviation that stands for environmental, social and governance, which are the non-financial factors in corporate reporting.

EU Medical Device Regulation (MDR)

Regulations created by the EU to ensure better protection for the public health and patient safety by establishing modernized and more robust EU legislation. All medical device manufacturers and distributors must comply with these regulations.

Intermittent pneumatic VTE prevention

A treatment that aims to enhance the circulation of blood in the deep veins of the legs, which helps reduce deep vein thrombosis (blood clot in the deep veins of the legs).

US Food and Drug Administration (FDA)

The US authority responsible for protecting the public health by carrying out regular inspections of, among other things, medical devices.

Pressure injuries

Sores that occur when blood flow to the skin is reduced by external pressure. Most common in patients with reduced mobility.

Prevention

Preventive activity/treatment.

VTE (venous thromboembolism)

The abbreviation VTE stands for venous thromboembolism – a blood clot in the veins, similar to DVT (above).

TELECONFERENCE

Fund managers, analysts and the media are invited to a teleconference on October 22 at 08:00 CEST.

A presentation will be held during the teleconference.

Watch the teleconference via the following link:

<https://events.inderes.com/arjo/q3-report-2026>

Participants who wish to ask verbal questions at the teleconference must register using the link below. Once registered, participants will receive a telephone number and ID number to use to log in to the conference.

Registration

link:

<https://events.inderes.com/arjo/q3-report-2026/dial-in>

Alternatively, use the following link to download the presentation:

<https://www.arjo.com/int/about-us/investors/reports--presentations/2026/>

A recording of the teleconference will be available for three years via the following link: <https://events.inderes.com/arjo/q3-report-2026>

FINANCIAL INFORMATION

Updated information on, for example, the Arjo share and corporate governance is available on Arjo's website www.arjo.com. The Annual Report, year-end report and interim reports are published in Swedish and English and are available for download at www.arjo.com.

The following financial statements will be published in 2026/2027:

January 28, 2027	Year-end report 2026
March-April 2027	2026 Annual Report
April 16, 2027	Interim report Jan-Mar 2027
April 19, 2027	Annual General Meeting 2027



CONTACT

Maria Nilsson

Executive Vice President, Communication & Public Relations
+46 734 244 515

maria.nilsson@arjo.com

Erik Roslund

Investor Relations & Corporate Communications Manager
+46 768 996 303

erik.roslund@arjo.com

This information is information that Arjo AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on October 22, 2026 at 07:00 a.m. CEST.

At Arjo, we believe that empowering movement within healthcare environments is essential to quality care. Our products and solutions for patient transfers, hygiene, disinfection, diagnostics, treating leg ulcers, prevention of pressure injuries and deep vein thrombosis, and our medical beds are all designed to promote mobility, safety and dignity in all care situations. With over 7,000 people worldwide and 65 years caring for patients and healthcare professionals, we are committed to driving healthier outcomes for people facing mobility challenges.

Arjo AB · Corp. Reg. No. 559092-8064 · Hans Michelsensgatan 10 · SE-211 20 Malmö · Sweden

www.arjo.com